Results
74,196 records
Include
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 5 | von Ahn LuisDirector, President & CEO, Co-Founder, 10% Owner |  DUOLDuolingo, Inc.Derivative conversion · 10b5-1 plan | C | $332K 23.0K sh | Sep 18, 2026 |
Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramEvery ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 5 | von Ahn LuisDirector, President & CEO, Co-Founder, 10% Owner | DUOLDuolingo, Inc. Derivative conversion · 10b5-1 plan | C | $332K 23.0K sh | Sep 18, 2026 |
| 5 | Krishnamurthy Balaji (A)Chief Financial Officer |  UBERUber Technologies, IncTax withholding | F | $43K 608 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 5 | Budur KumarCHIEF MEDICAL OFFICER |  HRMYHarmony Biosciences Holdings, Inc.Option exercise | M | — 900 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 5 | Fitzpatrick JenniferCLO and Head of Program Mgmt. |  SIONSionna Therapeutics, Inc.Disposition to issuer | D | — 103.1K sh | Sep 18, 2026 traded Sep 17, 2026 |
| 5 | Hazelbaker JillSee Remarks | UBERUber Technologies, Inc Option exercise | M | — 1,416 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 5 | Hazelbaker JillSee Remarks | UBERUber Technologies, Inc Option exercise | M | — 1,465 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 5 | Budur KumarCHIEF MEDICAL OFFICER | HRMYHarmony Biosciences Holdings, Inc. Option exercise | M | — 900 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 5 | Budur KumarCHIEF MEDICAL OFFICER | HRMYHarmony Biosciences Holdings, Inc. Option exercise | M | $12K 400 sh | Sep 18, 2026 traded Sep 17, 2026 |
| 5 | Aufderhaar DavidChief Financial Officer |  SFIXStitch Fix, Inc.Option exercise | M | — 43.9K sh | Sep 18, 2026 traded Sep 16, 2026 |
| 5 | Krishnamurthy Balaji (A)Chief Financial Officer | UBERUber Technologies, Inc Tax withholding | F | $24K 341 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 5 | Krishnamurthy Balaji (A)Chief Financial Officer | UBERUber Technologies, Inc Option exercise | M | — 490 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 5 | Flees Lori AnnDirector, President & CEO |  VVVVALVOLINE INCGrant or award | A | $974 36 sh | Sep 18, 2026 traded Sep 17, 2026 |
| 5 | Macdonald AndrewSee Remarks | UBERUber Technologies, Inc Tax withholding | F | $45K 634 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 5 | Krishnamurthy Balaji (A)Chief Financial Officer | UBERUber Technologies, Inc Tax withholding | F | $17K 245 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 4 | Offer OrChief Executive Officer |  SMWBSIMILARWEB LTD.Open-market sale · 10b5-1 plan | SELL | $254K 30.4K sh | Sep 18, 2026 traded Sep 17, 2026 |
| 4 | Lo FrancisChief People Officer |  ADPTAdaptive Biotechnologies CorpOpen-market sale · 10b5-1 plan | SELL | $225K 7,869 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 4 | Offer OrChief Executive Officer | SMWBSIMILARWEB LTD. Open-market sale · 10b5-1 plan | SELL | $384K 45.7K sh | Sep 18, 2026 traded Sep 16, 2026 |
| 3 | Sullivan Christopher RyanChief Financial Officer |  AVTXAvalo Therapeutics, Inc.Option exercise · 10b5-1 plan | M | $122K 12.4K sh | Sep 18, 2026 traded Sep 16, 2026 |
| 3 | Kumar MukulPRESIDENT, ENGINEERING |  PUBMPubMatic, Inc.Derivative conversion · 10b5-1 plan | C | — 8,000 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 3 | Kumar MukulPRESIDENT, ENGINEERING | PUBMPubMatic, Inc. Option exercise · 10b5-1 plan | M | $17K 8,000 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 3 | Azar Samak LChief Legal Officer |  GFSGLOBALFOUNDRIES Inc.Open-market sale · 10b5-1 plan | SELL | $15K 335 sh | Sep 18, 2026 traded Sep 17, 2026 |
| 3 | Wang LingkeDirector, President |  LIFEEthos Technologies Inc.Open-market sale · 10b5-1 plan | SELL | $12K 315 sh | Sep 18, 2026 traded Sep 17, 2026 |
| 3 | Colis Peter GeorgeDirector, CEO and Secretary | LIFEEthos Technologies Inc. Open-market sale · 10b5-1 plan | SELL | $12K 315 sh | Sep 18, 2026 traded Sep 17, 2026 |
| 3 | Kumar MukulPRESIDENT, ENGINEERING | PUBMPubMatic, Inc. Derivative conversion · 10b5-1 plan | C | — 8,000 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 3 | Lo FrancisChief People Officer | ADPTAdaptive Biotechnologies Corp Option exercise · 10b5-1 plan | M | — 15.6K sh | Sep 18, 2026 traded Sep 16, 2026 |
| 3 | Song EstherSee Remarks |  SYNASYNAPTICS IncOpen-market sale · 10b5-1 plan | SELL | $5,836 63 sh | Sep 18, 2026 traded Sep 18, 2026 |
| 3 | Lo FrancisChief People Officer | ADPTAdaptive Biotechnologies Corp Option exercise · 10b5-1 plan | M | — 23.4K sh | Sep 18, 2026 traded Sep 16, 2026 |
| 2 | Lo FrancisChief People Officer | ADPTAdaptive Biotechnologies Corp Option exercise · 10b5-1 plan | M | $190K 23.4K sh | Sep 18, 2026 traded Sep 16, 2026 |
| 2 | Lo FrancisChief People Officer | ADPTAdaptive Biotechnologies Corp Option exercise · 10b5-1 plan | M | $62K 15.6K sh | Sep 18, 2026 traded Sep 16, 2026 |
| 2 | Sousa Mauad BrunoDirector |  AUGOAura Minerals Inc.Derivative conversion | C | $37K 400 sh | Sep 18, 2026 traded Sep 17, 2026 |
| 1 | Navratil TomasCHIEF DEVELOPMENT OFFICER |  GKOSGLAUKOS CorpOpen-market sale · 10b5-1 plan | SELL | $57K 345 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 1 | Navratil TomasCHIEF DEVELOPMENT OFFICER | GKOSGLAUKOS Corp Open-market sale · 10b5-1 plan | SELL | $77K 460 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 1 | Matsuda MasaruSee Remarks |  ARQTArcutis Biotherapeutics, Inc.Open-market sale · 10b5-1 plan | SELL | $92K 3,674 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 0 | von Ahn LuisDirector, President & CEO, Co-Founder, 10% Owner | DUOLDuolingo, Inc. Option exercise · 10b5-1 plan | M | — 5,252 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 0 | Colis Peter GeorgeDirector, CEO and Secretary | LIFEEthos Technologies Inc. Derivative conversion · 10b5-1 plan | C | — 23.3K sh | Sep 18, 2026 traded Sep 18, 2026 |
| 0 | von Ahn LuisDirector, President & CEO, Co-Founder, 10% Owner | DUOLDuolingo, Inc. Derivative conversion · 10b5-1 plan | C | — 5,252 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 0 | Navratil TomasCHIEF DEVELOPMENT OFFICER | GKOSGLAUKOS Corp Open-market sale · 10b5-1 plan | SELL | $688 4 sh | Sep 18, 2026 traded Sep 16, 2026 |
| 0 | Wang LingkeDirector, President | LIFEEthos Technologies Inc. Derivative conversion · 10b5-1 plan | C | — 118.3K sh | Sep 18, 2026 traded Sep 17, 2026 |
| 0 | Sullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 12.4K sh | Sep 18, 2026 traded Sep 16, 2026 |
| 0 | Wang LingkeDirector, President | LIFEEthos Technologies Inc. Derivative conversion · 10b5-1 plan | C | — 118.3K sh | Sep 18, 2026 traded Sep 17, 2026 |